Well Care Compounding Pharmacy Issues Recall
The company recalls products due to sterility concerns.
FDA announced on May 17, 2016 that Well Care Compounding Pharmacy (Las Vegas, NV) is voluntarily recalling sterile compounded products distributed between Jan. 1–April 29, 2016. The recall comes after an FDA inspection of the facility that resulted in sterility assurance concerns.
The company states in a press release that it has not received any adverse events related to the products, as of May 17. However, because administration of a sterile product that may be compromised could result in serious infections or death, the company is advising customers to stop using the recalled products.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
